REFERENCES

Anaissie E, Paetznick V, Proffitt R, AdlerMoore J, Bodey G(1991). Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis., 10: 665-668.

Arora R, Sharma A (2010). Release studies of Ketoprofen Niosome Formulation. J. Chem. Pharm. Res., 2: 79 – 82.

Arunothayanum P, Bernard M, Craig D, Uchegbu I, Florence A (2000). The effect of processing variables on the physical characteristics of non-ionic surfactant vesicles (niosomes) formed from hexadecyl diglycerol ether. Int.J.Pharm., 201: 7-14.

Atiyeh B, Dibo S, Hayek S (2009). Wound cleansing, topical antiseptics and wound healing. Int Wound J., 1: 420–430.

Babiuk S., Bacaestrada M (2000). Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J. Control. Rel., 66: 199-214.

Balsubramaniam A, Kumar V, Pillai K (2002). Formulation and in-vivo evaluation of Niosome encapsulated Daunorubicin hydrochloride DDIP, 20: 1181-1193.

Baquero F (1997). Gram-positive resistance: challenge for the development of new antibiotics. Journal of Antimicrobial Chemotherapy, 39: 1–6.

Bastos M, Mondino P (1999). Molecular characterization and transfer among Staphylococcus strains of a plasmid conferring high-level resistance to mupirocin. European Journal of Clinical Microbiology and Infectious Diseases, 18: 393 - 398.

Benson H (2005) Transdermal drug delivery: Penetration enhancement techniques. Current Drug Deliv., 2: 23-33.

Carafa M, Marianecci C, Lucania G, Marchei E (2004). New vesicular ampicillin loaded delivery systems for topical applications: Characterisation, in-vivo permeation and anti-microbial activity. J. Controlled Release 95; 2004, 67-74.

Cevec G (1996) Transferosomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit. Rev. Ther. Drug Carrier Sys., 13: 257-388.

Date A, Naik B, Nagarsenkar M (2006). Novel drug delivery systems: Potential in improving topical delivery of anti-acne agents. Skin Pharmacol Physiol., 19: 2-16.

Essa E, Bonner M, Barry B (2003). Electroporation and ultradeformable liposomes;human skin barrier repair by phospholipid. J.Controlled Release, 92: 163–172.

Fernandez P, Willenbacher N, Frechen T, Kuhnle A (2005). Vesicles as rheology modifier, Colloids and Surfaces A: Physicochem. Eng. Aspects 262: 204–210.

Gillman G (1995). Analgesic, antipyretic and anti-inflammatory agents. Pharmacological basis of Therapeutics, 9: 639.

Gisby J, Bryant J (2000). Efficacy of a new cream formulation of Mupirocin: Comparision with oral and topical agents in Experimental skin infections. Antimicrob Agents Chemother., 44: 255- 60.

Gopinathan M (2002). New Insights into Skin Structure: Scratching the Surface. Adv. Drug Del. Rev., 54 (Suppl 1), 3-17.

Grahame R (1995). Transdermal NSAIDs, British J. Clinical Practice.49: 33-35.

Hans B, Bouwastra J (1994). Review: Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J. Controlled Release, 30: 1-15.

Hao Y, Zhao F, Y. Yang Y, Li K (2002). Studies on high encapsulation of colchicine by a niosome system, Int. J. Pharm., 244: 73-80.

Heather A, Benson E (2005). Transdermal drug delivery: penetration enhancement techniques. Curr. Drug Deli., 2: 23-33.

Hofland H, Bouwstra J, Verhoef J, Bucton G, Chowdry B, Ponec M, Junginger H (1992). Safety aspects of non-ionic surfactant vesicles: A toxicity study related to

physicochemical characteristics of non-ionic surfactants. J.Pharm Pharmacol., 44: 287-294.

Hofland J, Junginger H, (1994). Estradiol permeation from non-ionic surfactant vesicles through human stratum corneum *in vitro*. Pharm.Res., 11: 659-664.

Hu C. and Rhodes D (1999). Proniosomes: a novel drug carrier preparation. Int. J. Pharm., 185: 23-35.

Jia-You F, YannLii L, ChiaChun C, ChiaHsuan L, YiHung T (2004). Lipid nano/submicron emulsion as vehicle for topical flurbiprofen delivery. Drug Del., 11: 97-105.

Leski T, Gniadkowski M, Skoczynska A, Stefaniuk E, Trzcinski K & Hryniewicz W. (1999). Outbreak of mupirocinresistant staphylococci in a hospital in Warsaw, Poland, due to plasmid transmission and clonal spread of several strains. Journal of Clinical Microbiology, 37: 2781 - 2788.

Naik, A, Kalia Y, Richard H (2000). Transdermal drug delivery: overcoming the skin's barrier function. Elsevier Science Ltd.

Namdeo A, Jain N (2002). Liquid crystalline Pharmacogel based enhanced transdermal delivery of Propranalol Hydrochloride. J.Controlled Release, 82: 223-236.

P. Loan (2002). Transdermal Delivery of Pergolide from Surfactant-Based Elastic vesicles is superior to rigid vesicles: Characterization and in vitro transport studies. Pharmaceutical Research, 19: 991-997

Padamwar M, Pokharkar V (2006) Development of Vitamin loaded topical liposomal formulations using factorial design approach: Drug design and stability. Int.J.Pharm., 5: 11-20

Papps P, Rex J, Sobel J (2004). Guidelines for treatment of candidiasis. Clin. Infect.Dis., 38: 161-189.

Parasarathi G, Udupa N, Pillai G (1994). Formulation and in-vitro evaluation of vincristine encapsulated Niosomes. Ind. J. Pharm. Sci., 56: 90-94.

Parthasarathi G, Udupa N, Umadevi P and Pillai G (1994). Niosome encapsulated of vincristine sulfate: improved anticancer activity with reduced toxicity in mice. J. Drug Target, 2: 173-182.

Ralph E, Khazindar A, Barber K, and Grant C (1991). Comparative in vitro effects of liposomal amphotericin B, amphotericin B deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimum lethal concentration susceptibility studies and time-kill curves. Antimicrob. Agents Chemother., 35: 188-191.

Rewi D, Rao B, Apte S (2004). Ascorbyl Palmitate Vesicles (Aspasomes): Formation, characterisation and applications. Int.J.Pharm., 271: 95-113.

Sahiwala A, Misra A. (2002). Studies on topical application of niosomally entrapped Nimesulide. J.Pharm. Pharmaceut. Sci., 5: 220-225.

Schatzelin A, Cevc G (1998). Non-uniform cellular packing of the stratum corneum and permeability barrier function on intact skin: a high-resolution conofocal laser microscopy study using highly deformable vesicles (Transferosomes®). Brit. J. Dermatol. 138: 583-592.

Schmitz F, Fluit A, Gondolf M, Beyrau R, Lindenlauf E, Verhoef J (1999). The prevalence of aminoglycoside resistance and corresponding resistance genes in clinical isolates of staphylococci from 19 European hospitals. Journal of Antimicrobial Chemotherapy. 43: 253–9.

Schmook F, Meingassner J, Billich A (2001). Comparision of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption. Int.J.Pharm., 215: 51-56.

Schreier H (1989). Liposome and niosomes as a topical drug carriers: Dermal and Transdermal delivery. J. control release, 30: 863 - 868.

Spiclin P, Homar M, Zupancic A, Gasperlin M (2003). Sodium Ascorbyl phosphate in topical micro emulsions. Int. J. Pharm., 256: 65-73.

Tallau N (2010). Skin Absorption Modulation: Innovative Non-Hazardous Technologies for Topical Formulations. The Open Dermatology Journal, 4: 3-9.

Tamhankar A, Khandare J (1995). Niosomes novel drug delivery system. The Eastern Pharmacist, 39: 84-88.

Uchegbu I, Vyas S (1998). Non-ionic Surfactant based vesicles (Niosomes) in drug delivery. Int. J. Pharm., 172: 33-70.

Udo E, Farook V, Mokadas E, Jacob L & Sanyal S (1998). Molecular fingerprinting of mupirocin-resistant methicillin-resistant Staphylococcus aureus from a burn unit. International Journal of Infectious Disease 3: 82 - 87.

Vanhal D, Vanrensen A, Devringer T, Junginger H, and Bouwstra J (1996). Diffusion of estradiol from non ionic surfactant vesicles through human stratum corneum *in vitro*. STP Pharm.Sci., 6: 72–78.

Verhoef J, Fluit A (1999). The Sentry Participants Group. Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme. Journal of Antimicrobial Chemotherapy 43: 783–92.

Vrhovnik K, Krist J, Sentjure M (1998). Influence of liposome bilayer fluidity on the transport of encapsulated substances into the skin. Pharm. Res., 15: 525–530.

Wallace T, Paetznick V, Cossum P, Anaissie E (1997). Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob. Agents Chemother., 41: 2238-2243

Wallace T, Rex J (2002). *In vitro* activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates. J. Clin. Microbiol., 40: 1406-1412.

Xia W, Onyuksel H (2000). Mechanistic Studies on Surfactant- Induced Membrane Permeability Enhancement, Pharmaceutical Research, 17:612-618.